Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study

benzinga.com/news/health-care/25/06/45756147/jazz-pharmas-zepzelca-combo-shows-survival-edge-in-lung-cancer-study

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Monday revealed results from the Phase 3 IMforte study of Zepzelca (lurbinectedin) in combination with Roche Holdings AG’s (OTC:RHHBY) Tecentriq (atezolizumab) as a first-line maintenance treatment for extensive-stage small cell lung cancer…

This story appeared on benzinga.com, 2025-06-03 18:37:36.
The Entire Business World on a Single Page. Free to Use →